
Faron Pharmaceuticals appoints Jurriaan Dekkers as Chief Financial Officer
Esme Needham | December 3, 2025 | Appointment | | Faron Pharmaceuticals, chief financial officer
Faron Pharmaceuticals, a clinical-stage biopharmaceutical company, has appointed Jurriaan Dekkers as its new Chief Financial Officer (CFO).
Dekkers most recently served as CFO at ProQR Therapeutics, a biotechnology company focused on developing ribonucleic acid (RNA) therapies, and at AstraZeneca in the Netherlands. He was previously CEO of Acerta Pharma, part of the AstraZeneca Group, and has held finance roles at DaVita Medical Group and Sandvik.
Dekkers is currently a Supervisory Board member and Audit Committee member at Stichting Kinderpostzegels. He brings more than two decades of biopharma and healthcare experience to his new role.
Dr Jalkanen said of Dekkers: “His experience and proven track record of fundraising and strategic and commercial growth initiatives will support the advancement of our lead asset bexmarilimab as it enters the registrational study.”
The company’s current CFO, Yrjö Wichmann, is retiring, but will remain at Faron for a transitional period.
Related Content

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate
Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline …

US Department of Defense selects Faron for $6.1m COVID-19 research funding
The US Department of Defense (DoD) has selected Faron Pharmaceuticals’ HIBISCUS study to receive $6.1 …
Pharma manufacturing news in brief
Another J&J recall in the US, plus a round-up of product recalls, acquisitions, facility updates …






